Maizel Ari 4

What Happened
Maizel Ari, Chief Commercial Officer of Axsome Therapeutics (AXSM), received a grant of 7,224 performance stock units (PSUs) on April 21, 2026. The grant price reported is $0.00 because these are contingent awards (derivative securities) that will convert to common shares only if specified performance and service conditions are met. This is an award/grant (code A), not a purchase or sale.

Key Details

• Transaction date: 2026-04-21; reported on Form 4 filed 2026-04-23 (timely filing).
• Grant: 7,224 PSUs; reported acquisition price $0.00 (derivative award).
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnotes:
  • F1: Each PSU represents a contingent right to receive one share of common stock.
  • F2: PSUs vest only upon achievement of specified sales and commercial launch milestones and subject to continued service as of each vesting date.
• Transaction code: A (award/grant of a derivative security).

Context
PSUs are contingent awards that only become actual shares if performance targets and continued employment conditions are met; they carry no immediate cash proceeds. Such grants are common for executive compensation and retention and do not, by themselves, indicate buying or selling sentiment. If and when the PSUs vest, the eventual number of shares received and their value will depend on the vesting outcome and Axsome’s stock price at that time.